Sandostatin LAR · DIN 02239324 · 20 mg · injection Kit Pk
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Sandostatin LAR · DIN 02239324
Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02
Health Canada: Marketed since 1999-01-27 · brand SANDOSTATIN LAR · ATC H01CB02 OCTREOTIDE · form Powder for suspension (sustained-release · route Intramuscular · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 20 MG/VIAL · company Novartis pharmaceuticals canada inc · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02239324)
Source record
DIN 02239324: Sandostatin LAR
Raw flags: sec3=Y
Item: 920000333; group id 942; item number 2241; lccId None; manufacturer id NOV
Source form: Inj Kit Pk; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $1706.5800; ministry $938.6190
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239324
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62793
Interchangeable products
Octreotide Depot · DIN 02567784 · $938.6190
Shortage status: not checked (no credentials)